Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
Marianne Hütt-Cabezas(NYU Langone Health), Fausto J. Rodríguez(University of California, Los Angeles), David Zagzag(NYU Langone Health), Charles G. Eberhart(Johns Hopkins University), Eric H. Raabe(Johns Hopkins University), Elisabeth J. Rushing(University Hospital of Zurich), Smit Shah(NYU Langone Health), Deepali Jain(Johns Hopkins University), Iren Horkayne‐Szakaly(Walter Reed National Military Medical Center), J. Douglas Cameron(Hennepin County), Matthias A. Karajannis(NYU Langone Health)
Cited by 80
Related Papers
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Altered Telomeres in Tumors with <i>ATRX</i> and <i>DAXX</i> Mutations
|Science|2011|1.1k